Gilead Sciences, the maker of the first covid-19 treatment found to have worked in clinical trials, remdesivir, said Monday it will charge U.S. hospitals $3,120 for the typical patient with private insurance. Hannah Denham, Yasmeen Abutaleb, and Christopher Rowland write in the Washington Post that sSoon after the announcement, the Trump administration said it had secured nearly all of the company’s supply of the drug for use in U.S. hospitals through September, with a contract for 500,000 treatment courses, which it will make available to hospitals at Gilead’s price.